Annual Net Income
-$39.48 M
+$4.69 M+10.62%
December 31, 2023
Summary
- As of February 7, 2025, ONCT annual net profit is -$39.48 million, with the most recent change of +$4.69 million (+10.62%) on December 31, 2023.
- During the last 3 years, ONCT annual net income has fallen by -$22.25 million (-129.20%).
- ONCT annual net income is now -358.13% below its all-time high of $15.29 million, reached on December 31, 2010.
Performance
ONCT Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Net Income
-$8.46 M
+$95.00 K+1.11%
September 30, 2024
Summary
- As of February 7, 2025, ONCT quarterly net profit is -$8.46 million, with the most recent change of +$95.00 thousand (+1.11%) on September 30, 2024.
- Over the past year, ONCT quarterly net income has dropped by -$76.00 thousand (-0.91%).
- ONCT quarterly net income is now -119.09% below its all-time high of $44.34 million, reached on March 31, 2010.
Performance
ONCT Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Net Income
-$34.58 M
+$1.40 M+3.89%
September 30, 2024
Summary
- As of February 7, 2025, ONCT TTM net profit is -$34.58 million, with the most recent change of +$1.40 million (+3.89%) on September 30, 2024.
- Over the past year, ONCT TTM net income has increased by +$1.80 million (+4.96%).
- ONCT TTM net income is now -224.88% below its all-time high of $27.69 million, reached on June 30, 2016.
Performance
ONCT TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Net Income Formula
Net Income = Revenue − COGS − Operating Expenses − Interest − Taxes − Other Expenses
ONCT Net Income Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10.6% | -0.9% | +5.0% |
| 3 y3 years | -129.2% | +26.3% | +24.4% |
| 5 y5 years | -2.8% | +26.3% | +24.4% |
ONCT Net Income Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -26.0% | +10.6% | -4.8% | +27.9% | -10.3% | +24.4% |
| 5 y | 5-year | -129.2% | +10.6% | -231.0% | +27.9% | -100.7% | +24.4% |
| alltime | all time | -358.1% | +23.8% | -119.1% | +82.3% | -224.9% | +50.5% |
Oncternal Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$8.46 M(-1.1%) | -$34.58 M(-3.9%) |
| Jun 2024 | - | -$8.56 M(+2.0%) | -$35.97 M(-1.1%) |
| Mar 2024 | - | -$8.39 M(-8.5%) | -$36.38 M(-7.8%) |
| Dec 2023 | -$39.48 M(-10.6%) | -$9.16 M(-7.1%) | -$39.48 M(-5.4%) |
| Sep 2023 | - | -$9.86 M(+10.0%) | -$41.72 M(-2.9%) |
| Jun 2023 | - | -$8.97 M(-21.9%) | -$42.98 M(-6.1%) |
| Mar 2023 | - | -$11.49 M(+0.8%) | -$45.75 M(+3.6%) |
| Dec 2022 | -$44.17 M(+41.0%) | -$11.40 M(+2.5%) | -$44.17 M(+8.1%) |
| Sep 2022 | - | -$11.13 M(-5.2%) | -$40.84 M(+3.8%) |
| Jun 2022 | - | -$11.74 M(+18.5%) | -$39.35 M(+11.5%) |
| Mar 2022 | - | -$9.90 M(+22.7%) | -$35.29 M(+12.6%) |
| Dec 2021 | -$31.33 M(+81.9%) | -$8.07 M(-16.2%) | -$31.33 M(+21.4%) |
| Sep 2021 | - | -$9.63 M(+25.4%) | -$25.82 M(+25.4%) |
| Jun 2021 | - | -$7.68 M(+29.2%) | -$20.58 M(+11.6%) |
| Mar 2021 | - | -$5.95 M(+132.6%) | -$18.43 M(+7.0%) |
| Dec 2020 | -$17.23 M(-49.6%) | -$2.56 M(-41.8%) | -$17.23 M(-8.5%) |
| Sep 2020 | - | -$4.39 M(-20.6%) | -$18.82 M(-2.6%) |
| Jun 2020 | - | -$5.54 M(+16.8%) | -$19.32 M(-47.3%) |
| Mar 2020 | - | -$4.74 M(+14.0%) | -$36.63 M(-2.8%) |
| Dec 2019 | -$34.19 M(-11.0%) | -$4.16 M(-15.0%) | -$37.70 M(-3.2%) |
| Sep 2019 | - | -$4.89 M(-78.6%) | -$38.95 M(-10.4%) |
| Jun 2019 | - | -$22.85 M(+293.8%) | -$43.49 M(+41.8%) |
| Mar 2019 | - | -$5.80 M(+7.1%) | -$30.66 M(-20.2%) |
| Dec 2018 | -$38.42 M(+26.2%) | -$5.42 M(-42.6%) | -$38.42 M(-9.1%) |
| Sep 2018 | - | -$9.43 M(-5.8%) | -$42.28 M(+2.2%) |
| Jun 2018 | - | -$10.02 M(-26.1%) | -$41.35 M(+9.6%) |
| Mar 2018 | - | -$13.56 M(+46.1%) | -$37.74 M(+24.0%) |
| Dec 2017 | -$30.44 M(+71.7%) | -$9.28 M(+9.1%) | -$30.44 M(+8.6%) |
| Sep 2017 | - | -$8.50 M(+32.8%) | -$28.03 M(+6.0%) |
| Jun 2017 | - | -$6.41 M(+2.4%) | -$26.44 M(+1.4%) |
| Mar 2017 | - | -$6.25 M(-8.9%) | -$26.08 M(+47.2%) |
| Dec 2016 | -$17.72 M(-5.2%) | -$6.86 M(-0.7%) | -$17.72 M(+25.8%) |
| Sep 2016 | - | -$6.91 M(+14.2%) | -$14.09 M(-150.9%) |
| Jun 2016 | - | -$6.05 M(-387.4%) | $27.69 M(-294.8%) |
| Mar 2016 | - | $2.11 M(-165.1%) | -$14.21 M(-24.0%) |
| Dec 2015 | -$18.70 M(-52.5%) | -$3.23 M(-109.3%) | -$18.70 M(-37.7%) |
| Sep 2015 | - | $34.87 M(-172.7%) | -$30.02 M(-57.0%) |
| Jun 2015 | - | -$47.95 M(+1911.4%) | -$69.82 M(+112.8%) |
| Mar 2015 | - | -$2.38 M(-83.6%) | -$32.81 M(-16.8%) |
| Dec 2014 | -$39.41 M(-6.4%) | -$14.54 M(+194.7%) | -$39.41 M(+20.7%) |
| Sep 2014 | - | -$4.93 M(-54.9%) | -$32.66 M(-10.9%) |
| Jun 2014 | - | -$10.94 M(+21.8%) | -$36.66 M(-4.8%) |
| Mar 2014 | - | -$8.99 M(+15.4%) | -$38.52 M(-8.5%) |
| Dec 2013 | -$42.11 M | -$7.79 M(-12.8%) | -$42.11 M(-6.5%) |
| Sep 2013 | - | -$8.94 M(-30.2%) | -$45.04 M(+45.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2013 | - | -$12.80 M(+1.7%) | -$31.00 M(+8.5%) |
| Mar 2013 | - | -$12.58 M(+17.4%) | -$28.58 M(+5.5%) |
| Dec 2012 | -$27.07 M(-18.7%) | -$10.71 M(-310.1%) | -$27.07 M(+0.1%) |
| Sep 2012 | - | $5.10 M(-149.1%) | -$27.04 M(-34.8%) |
| Jun 2012 | - | -$10.38 M(-6.3%) | -$41.49 M(-0.7%) |
| Mar 2012 | - | -$11.08 M(+3.7%) | -$41.78 M(+25.5%) |
| Dec 2011 | -$33.29 M(-317.7%) | -$10.68 M(+14.3%) | -$33.29 M(+10.5%) |
| Sep 2011 | - | -$9.34 M(-12.5%) | -$30.14 M(+2.6%) |
| Jun 2011 | - | -$10.67 M(+311.3%) | -$29.37 M(-7.2%) |
| Mar 2011 | - | -$2.60 M(-65.5%) | -$31.64 M(-306.9%) |
| Dec 2010 | $15.29 M(-133.1%) | -$7.53 M(-12.2%) | $15.29 M(+28.0%) |
| Sep 2010 | - | -$8.57 M(-33.7%) | $11.95 M(+55.1%) |
| Jun 2010 | - | -$12.94 M(-129.2%) | $7.70 M(-17.9%) |
| Mar 2010 | - | $44.34 M(-507.7%) | $9.38 M(-120.3%) |
| Dec 2009 | -$46.26 M(-10.7%) | -$10.88 M(-15.2%) | -$46.26 M(-6.1%) |
| Sep 2009 | - | -$12.82 M(+13.9%) | -$49.25 M(+1.8%) |
| Jun 2009 | - | -$11.26 M(-0.4%) | -$48.35 M(-3.9%) |
| Mar 2009 | - | -$11.30 M(-18.5%) | -$50.34 M(-2.8%) |
| Dec 2008 | -$51.78 M(+28.3%) | -$13.87 M(+16.3%) | -$51.78 M(+2.1%) |
| Sep 2008 | - | -$11.93 M(-9.9%) | -$50.70 M(+3.4%) |
| Jun 2008 | - | -$13.24 M(+3.9%) | -$49.02 M(+9.0%) |
| Mar 2008 | - | -$12.74 M(-0.4%) | -$44.98 M(+11.4%) |
| Dec 2007 | -$40.36 M(+13.7%) | -$12.79 M(+24.9%) | -$40.36 M(+25.0%) |
| Sep 2007 | - | -$10.24 M(+11.3%) | -$32.28 M(-2.0%) |
| Jun 2007 | - | -$9.20 M(+13.3%) | -$32.93 M(-2.3%) |
| Mar 2007 | - | -$8.12 M(+72.4%) | -$33.71 M(-5.1%) |
| Dec 2006 | -$35.51 M(-3.6%) | -$4.71 M(-56.7%) | -$35.51 M(-8.0%) |
| Sep 2006 | - | -$10.89 M(+9.1%) | -$38.59 M(+2.5%) |
| Jun 2006 | - | -$9.98 M(+0.6%) | -$37.65 M(-0.1%) |
| Mar 2006 | - | -$9.92 M(+27.3%) | -$37.68 M(+2.3%) |
| Dec 2005 | -$36.84 M(+64.8%) | -$7.80 M(-21.6%) | -$36.84 M(+2.5%) |
| Sep 2005 | - | -$9.94 M(-0.8%) | -$35.93 M(+15.5%) |
| Jun 2005 | - | -$10.02 M(+10.4%) | -$31.11 M(+21.5%) |
| Mar 2005 | - | -$9.08 M(+31.9%) | -$25.61 M(+14.6%) |
| Dec 2004 | -$22.35 M(+57.4%) | -$6.88 M(+34.3%) | -$22.35 M(+11.7%) |
| Sep 2004 | - | -$5.13 M(+13.4%) | -$20.01 M(+9.4%) |
| Jun 2004 | - | -$4.52 M(-22.4%) | -$18.29 M(+6.1%) |
| Mar 2004 | - | -$5.82 M(+28.0%) | -$17.23 M(+21.4%) |
| Dec 2003 | -$14.19 M(+19.6%) | -$4.55 M(+33.7%) | -$14.19 M(+47.1%) |
| Sep 2003 | - | -$3.40 M(-1.8%) | -$9.65 M(+54.5%) |
| Jun 2003 | - | -$3.46 M(+24.6%) | -$6.25 M(+124.6%) |
| Mar 2003 | - | -$2.78 M | -$2.78 M |
| Dec 2002 | -$11.87 M(+47.2%) | - | - |
| Dec 2001 | -$8.06 M(+111.5%) | - | - |
| Dec 2000 | -$3.81 M(+408.3%) | - | - |
| Dec 1999 | -$750.00 K | - | - |
FAQ
- What is Oncternal Therapeutics annual net profit?
- What is the all time high annual net income for Oncternal Therapeutics?
- What is Oncternal Therapeutics annual net income year-on-year change?
- What is Oncternal Therapeutics quarterly net profit?
- What is the all time high quarterly net income for Oncternal Therapeutics?
- What is Oncternal Therapeutics quarterly net income year-on-year change?
- What is Oncternal Therapeutics TTM net profit?
- What is the all time high TTM net income for Oncternal Therapeutics?
- What is Oncternal Therapeutics TTM net income year-on-year change?
What is Oncternal Therapeutics annual net profit?
The current annual net income of ONCT is -$39.48 M
What is the all time high annual net income for Oncternal Therapeutics?
Oncternal Therapeutics all-time high annual net profit is $15.29 M
What is Oncternal Therapeutics annual net income year-on-year change?
Over the past year, ONCT annual net profit has changed by +$4.69 M (+10.62%)
What is Oncternal Therapeutics quarterly net profit?
The current quarterly net income of ONCT is -$8.46 M
What is the all time high quarterly net income for Oncternal Therapeutics?
Oncternal Therapeutics all-time high quarterly net profit is $44.34 M
What is Oncternal Therapeutics quarterly net income year-on-year change?
Over the past year, ONCT quarterly net profit has changed by -$76.00 K (-0.91%)
What is Oncternal Therapeutics TTM net profit?
The current TTM net income of ONCT is -$34.58 M
What is the all time high TTM net income for Oncternal Therapeutics?
Oncternal Therapeutics all-time high TTM net profit is $27.69 M
What is Oncternal Therapeutics TTM net income year-on-year change?
Over the past year, ONCT TTM net profit has changed by +$1.80 M (+4.96%)